Platelets can contain SARS-CoV-2 RNA and are hyperactivated in COVID-19

Younes Zaid; Florian Puhm; Isabelle Allaeys; Abdallah Naya; Mounia Oudghiri; Loubna Khalki; Youness Limami; Nabil Zaid; Khalid Sadki; Rafiqua Ben El Haj; Wissal Maher; Belayachi Lamiae; Bouchra Belefquih; Amina Benouda; Amine Cheikh; Yahia Cherrah; Louis Flamand; Fadila Guessous; Eric Boilard

doi:10.1101/2020.06.23.20137596

ABSTRACT

Rationale In addition to the overwhelming lung inflammation that prevails in COVID-19, hypercoagulation and thrombosis contribute to the lethality of subjects infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Platelets are chiefly implicated in thrombosis. Moreover, they can interact with viruses and are an important source of inflammatory mediators. While a lower platelet count is associated with severity and mortality, little is known about platelet function during COVID-19.

Objective To evaluate the contribution of platelets to inflammation and thrombosis in COVID-19 patients.

Methods and Results We document the presence of SARS-CoV-2 RNA in platelets of COVID-19 patients. Exhaustive assessment of cytokines in plasma and in platelets revealed the modulation of platelet-associated cytokine levels in COVID-19, pointing to a direct contribution of platelets to the plasmatic cytokine load. Moreover, we demonstrate that platelets release their alpha- and dense-granule contents and phosphatidylserine-exposing extracellular vesicles. Functionally, platelets were hyperactivated in COVID-19 subjects, with aggregation occurring at suboptimal thrombin concentrations. Furthermore, platelets adhered more efficiently onto collagen-coated surfaces under flow conditions.

Conclusions These data suggest that platelets could participate in the dissemination of SARS-CoV-2 and in the overwhelming thrombo-inflammation observed in COVID-19. Thus, blockade of platelet activation pathways may improve outcomes in this disease.

KEY POINTS Platelets are a source of inflammatory cytokines and degranulate in COVID-19 Platelets contain SARS-CoV-2 RNA molecules and are prone to activation in COVID-19

Subject terms Infectious diseases/Emerging infectious diseases, SARS-CoV-2, COVID-19, Hematology, Platelets

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was supported by Cheikh Zaid Foundation and the Canadian Institutes of Health Research (to LF). EB is recipient of senior award from the Fonds de Recherche du Quebec en Sante (FRQS). FP is recipient of a postdoctoral fellowship from FRQS

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Local Ethics Committee of Cheikh Zaid Hospital, Rabat, Morocco, Project: CEFCZ/PR/2020-PR04

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data, analytic methods and study materials supporting the findings of this study are provided in the manuscript, supplemental material and available from the corresponding author upon reasonable request.